doi: 10.1016/j.celrep.2018.10.018 6 CapozziMESvendsenBEnciscoSELewandowskiSLMartinMDLinHet al
GLP-1 RAs are preferred second-line agents in patients with T2DM with established atherosclerotic cardiovascular diseases (ASCVD) in light of their demonstrated ASCVD benefit, high efficacy, low potential for hypoglycaemia and potential for weight loss
These findings link low IGF-1 levels with certain measures of frailty, but the researchers werent able to prove a direct cause
- Should reapply every 2-4 hours
There is increasing recognition of the impact of obesity on workforce health (and as a result, on GDP), which further strengthens the case for healthcare systems investing more to enable additional widespread uptake of GLP-1RAs
So, in this case, the water retention can be an indirect side effect of the peptide's primary effect on appetite